CA3134531A1 - Anesthetic composition and method of anesthetizing the eye - Google Patents

Anesthetic composition and method of anesthetizing the eye Download PDF

Info

Publication number: CA3134531A1
Authority: CA; Canada
Prior art keywords: composition; articaine; mannitol; buffer; borate
Prior art date: 2019-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA3134531A

Other languages

English (en)

French (fr)

Inventor

Martin Uram

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-03-26

Filing date

2020-03-16

Publication date

2020-10-01

2019-03-27 Priority claimed from PCT/US2019/024239 external-priority patent/WO2019191200A1/en

2020-03-16 Application filed by Individual filed Critical Individual

2020-10-01 Publication of CA3134531A1 publication Critical patent/CA3134531A1/en

Status Pending legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 279
230000003444 anaesthetic effect Effects 0.000 title claims abstract description 108
238000000034 method Methods 0.000 title claims description 37
229960003831 articaine Drugs 0.000 claims abstract description 206
QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims abstract description 205
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 104
239000000872 buffer Substances 0.000 claims abstract description 77
235000010355 mannitol Nutrition 0.000 claims abstract description 72
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 43
239000004327 boric acid Substances 0.000 claims abstract description 42
239000000594 mannitol Substances 0.000 claims abstract description 42
229930195725 Mannitol Natural products 0.000 claims abstract description 40
238000009472 formulation Methods 0.000 claims abstract description 29
206010002091 Anaesthesia Diseases 0.000 claims abstract description 19
230000037005 anaesthesia Effects 0.000 claims abstract description 19
150000001642 boronic acid derivatives Chemical group 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 56
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 34
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
235000017281 sodium acetate Nutrition 0.000 claims description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 15
150000005846 sugar alcohols Chemical class 0.000 claims description 14
239000001632 sodium acetate Substances 0.000 claims description 13
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 6
239000000600 sorbitol Substances 0.000 claims description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 4
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 claims description 2
235000017454 sodium diacetate Nutrition 0.000 claims description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 3
229940009662 edetate Drugs 0.000 claims 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
230000000699 topical effect Effects 0.000 abstract description 94
239000003963 antioxidant agent Substances 0.000 abstract description 6
239000000654 additive Substances 0.000 abstract description 3
229920000609 methyl cellulose Polymers 0.000 abstract description 3
239000001923 methylcellulose Substances 0.000 abstract description 3
238000010494 dissociation reaction Methods 0.000 abstract description 2
230000005593 dissociations Effects 0.000 abstract description 2
239000002674 ointment Substances 0.000 abstract description 2
239000007864 aqueous solution Substances 0.000 abstract 1
235000010338 boric acid Nutrition 0.000 description 34
239000007924 injection Substances 0.000 description 30
238000002347 injection Methods 0.000 description 30
LUPKINKNYDFRIB-UHFFFAOYSA-N 4-methyl-3-[2-(propylazaniumyl)propanoylamino]thiophene-2-carboxylate Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(O)=O LUPKINKNYDFRIB-UHFFFAOYSA-N 0.000 description 16
229960000583 acetic acid Drugs 0.000 description 16
239000006196 drop Substances 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 14
150000001875 compounds Chemical class 0.000 description 11
210000000795 conjunctiva Anatomy 0.000 description 10
238000003860 storage Methods 0.000 description 10
235000011054 acetic acid Nutrition 0.000 description 9
210000004087 cornea Anatomy 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
239000003193 general anesthetic agent Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
239000012362 glacial acetic acid Substances 0.000 description 7
230000000694 effects Effects 0.000 description 6
230000007774 longterm Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
229930182837 (R)-adrenaline Natural products 0.000 description 5
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 5
-1 D-mannitol Chemical class 0.000 description 5
229940035674 anesthetics Drugs 0.000 description 5
235000006708 antioxidants Nutrition 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
229960005139 epinephrine Drugs 0.000 description 5
239000003889 eye drop Substances 0.000 description 5
230000007794 irritation Effects 0.000 description 5
229940087562 sodium acetate trihydrate Drugs 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
238000011200 topical administration Methods 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
210000003161 choroid Anatomy 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000003589 local anesthetic agent Substances 0.000 description 4
230000036407 pain Effects 0.000 description 4
210000001525 retina Anatomy 0.000 description 4
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
230000000087 stabilizing effect Effects 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
230000002411 adverse Effects 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
230000003078 antioxidant effect Effects 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
125000004185 ester group Chemical group 0.000 description 3
239000012458 free base Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
239000002997 ophthalmic solution Substances 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
238000012360 testing method Methods 0.000 description 3
PBKADZMAZVCJMR-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;dihydrate Chemical compound O.O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O PBKADZMAZVCJMR-UHFFFAOYSA-N 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229940061607 dibasic sodium phosphate Drugs 0.000 description 2
150000004683 dihydrates Chemical class 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
229940124274 edetate disodium Drugs 0.000 description 2
206010014801 endophthalmitis Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
210000004561 lacrimal apparatus Anatomy 0.000 description 2
229960004194 lidocaine Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229940054534 ophthalmic solution Drugs 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000003002 pH adjusting agent Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 2
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
235000010265 sodium sulphite Nutrition 0.000 description 2
229940080150 systane Drugs 0.000 description 2
239000005526 vasoconstrictor agent Substances 0.000 description 2
239000004034 viscosity adjusting agent Substances 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
QGBLCIBATKETJC-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;manganese(2+) Chemical compound [Mn+2].O1B([O-])OB2OB([O-])OB1O2 QGBLCIBATKETJC-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010061951 Methemoglobin Proteins 0.000 description 1
101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
241000588770 Proteus mirabilis Species 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000003732 agents acting on the eye Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229960002279 articaine hydrochloride Drugs 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
URSLCTBXQMKCFE-UHFFFAOYSA-N dihydrogenborate Chemical compound OB(O)[O-] URSLCTBXQMKCFE-UHFFFAOYSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004941 influx Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000007830 nerve conduction Effects 0.000 description 1
229940125702 ophthalmic agent Drugs 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
229930010796 primary metabolite Natural products 0.000 description 1
238000011165 process development Methods 0.000 description 1
229960003981 proparacaine Drugs 0.000 description 1
125000006308 propyl amino group Chemical group 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
239000003860 topical agent Substances 0.000 description 1
229940100613 topical solution Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
VLCLHFYFMCKBRP-UHFFFAOYSA-N tricalcium;diborate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]B([O-])[O-].[O-]B([O-])[O-] VLCLHFYFMCKBRP-UHFFFAOYSA-N 0.000 description 1
NFMWFGXCDDYTEG-UHFFFAOYSA-N trimagnesium;diborate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]B([O-])[O-].[O-]B([O-])[O-] NFMWFGXCDDYTEG-UHFFFAOYSA-N 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
229920001664 tyloxapol Polymers 0.000 description 1
229960004224 tyloxapol Drugs 0.000 description 1
230000002568 urticarial effect Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Ophthalmology & Optometry (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Anesthesiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA3134531A 2019-03-26 2020-03-16 Anesthetic composition and method of anesthetizing the eye Pending CA3134531A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201962824207P	2019-03-26	2019-03-26
US62/824,207		2019-03-26
USPCT/US2019/024239		2019-03-27
PCT/US2019/024239 WO2019191200A1 (en)	2018-03-27	2019-03-27	Method and formulation for producing anesthesia of internal aspect of eye wall by topical application
US16/811,798 US11096922B2 (en)	2018-03-27	2020-03-06	Anesthetic composition and method of anesthetizing the eye
US16/811,798		2020-03-06
PCT/US2020/022915 WO2020197816A1 (en)	2019-03-26	2020-03-16	Anesthetic composition and method of anesthetizing the eye

Publications (1)

Publication Number	Publication Date
CA3134531A1 true CA3134531A1 (en)	2020-10-01

Family

ID=72609654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3134531A Pending CA3134531A1 (en)	2019-03-26	2020-03-16	Anesthetic composition and method of anesthetizing the eye

Country Status (11)

Country	Link
EP (1)	EP3946311A4 (zh)
JP (1)	JP2022527621A (zh)
KR (1)	KR20210143254A (zh)
CN (1)	CN114072139A (zh)
AU (1)	AU2020245203A1 (zh)
BR (1)	BR112021019039A2 (zh)
CA (1)	CA3134531A1 (zh)
IL (1)	IL286624A (zh)
MX (1)	MX2021011589A (zh)
SG (1)	SG11202110423UA (zh)
WO (1)	WO2020197816A1 (zh)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69333850T3 (de) *	1992-05-06	2011-03-17	Alcon Laboratories, Inc., Fort Worth	Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
ES2383003T3 (es) *	2001-11-21	2012-06-15	Carl Zeiss Meditec Sas	Composición para estabilizar ácido hialurónico
CN101695488B (zh) *	2009-11-05	2012-05-02	蚌埠丰原涂山制药有限公司	复方阿替卡因注射用冻干制剂及其制备方法
CN101721407B (zh) *	2009-11-23	2013-04-10	蚌埠丰原涂山制药有限公司	复方盐酸阿替卡因注射液及其制备方法
FR2968996B1 (fr) *	2010-12-17	2013-04-12	Anteis Sa	Formulation aqueuse injectable sterile utilisee en ophtalmologie
FR3036035B1 (fr) *	2015-05-11	2018-10-05	Laboratoires Vivacy	Compositions comprenant au moins un polyol et au moins un anesthesique
JP2018526423A (ja) *	2015-09-08	2018-09-13	ビューポイントセラピューティクス，インコーポレイテッド	眼科疾患を処置するための化合物および製剤
WO2018220283A1 (fr) *	2017-05-29	2018-12-06	Kh Medtech Sarl	Composition injectable sterile contenant de l'acide hyaluronique reticule et de l'articaine

2020
- 2020-03-16 SG SG11202110423UA patent/SG11202110423UA/en unknown
- 2020-03-16 MX MX2021011589A patent/MX2021011589A/es unknown
- 2020-03-16 AU AU2020245203A patent/AU2020245203A1/en active Pending
- 2020-03-16 KR KR1020217034148A patent/KR20210143254A/ko unknown
- 2020-03-16 CA CA3134531A patent/CA3134531A1/en active Pending
- 2020-03-16 EP EP20776365.7A patent/EP3946311A4/en active Pending
- 2020-03-16 JP JP2021560140A patent/JP2022527621A/ja active Pending
- 2020-03-16 CN CN202080033483.9A patent/CN114072139A/zh active Pending
- 2020-03-16 BR BR112021019039A patent/BR112021019039A2/pt unknown
- 2020-03-16 WO PCT/US2020/022915 patent/WO2020197816A1/en active Application Filing
2021
- 2021-09-23 IL IL286624A patent/IL286624A/en unknown

Also Published As

Publication number	Publication date
IL286624A (en)	2021-10-31
WO2020197816A1 (en)	2020-10-01
MX2021011589A (es)	2021-12-15
EP3946311A4 (en)	2022-12-28
SG11202110423UA (en)	2021-10-28
AU2020245203A1 (en)	2021-11-11
BR112021019039A2 (pt)	2021-11-30
JP2022527621A (ja)	2022-06-02
EP3946311A1 (en)	2022-02-09
CN114072139A (zh)	2022-02-18
KR20210143254A (ko)	2021-11-26

Legal Events

Date	Code	Title	Description
2024-02-21	EEER	Examination request	Effective date: 20240220

Publication	Publication Date	Title
US8759401B2 (en)	2014-06-24	Aqueous gel formulation and method for inducing topical anesthesia
Shah et al.	2010	A novel lidocaine hydrochloride ophthalmic gel for topical ocular anesthesia
EP2257275B1 (en)	2011-12-28	Ketorolac tromethamine compositions for treating or preventing ocular pain
KR20120112537A (ko)	2012-10-11	무자극성 안과용 포비돈-요오드 조성물
CN103747786A (zh)	2014-04-23	比马前列素和溴莫尼定的固定剂量组合
US11850213B2 (en)	2023-12-26	Ophthalmic compositions of rifamycins and uses thereof
AU2021221401B2 (en)	2023-11-09	Stable peptide compositions
ES2540151B1 (es)	2016-02-29	Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
US10973758B2 (en)	2021-04-13	Methods of eye treatment using therapeutic compositions containing dipyridamole
US20240041824A1 (en)	2024-02-08	Anesthetic composition and method of anesthetizing the eye
JP6889176B2 (ja)	2021-06-18	眼痛を予防及び治療するためのアミノホスフィン酸誘導体
JP6934581B2 (ja)	2021-09-15	エピナスチン又はその塩を含有する水性医薬組成物
JP3502574B2 (ja)	2004-03-02	眼感染症治療用眼軟膏剤
BR112021000240A2 (pt)	2021-04-06	Composições oftálmicas que contêm uma prostamida que libera óxido nítrico
CA3134531A1 (en)	2020-10-01	Anesthetic composition and method of anesthetizing the eye
RU2812900C2 (ru)	2024-02-05	Анестезирующая композиция и способ анестезирования глаза
Bellucci et al.	2012	Comparative efficacy of topical tetracaine solution versus lidocaine gel in cataract surgery
US20230025836A1 (en)	2023-01-26	Eye drop composition for preventing or treating eye disease
CA3088185C (en)	2024-01-02	Suspension compositions of multi-target inhibitors
WO2021224815A1 (en)	2021-11-11	Stable aqueous parenteral solutions of nonsteroidal anti-inflammatory drug (nsaid)